Active Biotech Capital Markets Day

(Thomson Reuters ONE) -


Lund, Sweden, June 10, 2010 - Today, Active Biotech AB (NASDAQ OMX Nordic: ACTI)
is holding a capital markets day for analysts, investors and media at IVA
Conference Center in Stockholm. An update on the company's project portfolio
will be given as well as a more in depth presentation of the TASQ prostate
cancer project and proposed Phase III outline. The agenda for the day is as
follows:

Time (CEST)

14:00 - 14:05      Welcome and introduction          Tomas Leanderson

14:05 - 14:40      Project portfolio                         Tomas Leanderson

14:40 - 14:45      Q & A

14:45 - 15:25      TASQ Phase II                          Göran Forsberg

15:25 - 15:35      Q & A

15:35 - 15:45      TASQ Phase III outline              Tomas Leanderson

15:45 - 15:55      Active Biotech going forward     Tomas Leanderson

15:55- 16:00       Q & A



The Capital Markets Day will also be available to follow via Active Biotech's
website from 14:00 CEST at www.activebiotech.com
.



Active Biotech AB (publ)

Tomas Leanderson

President and CEO





About Active Biotech
Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology company with
focus on autoimmune/inflammatory diseases and cancer. Projects in pivotal phase
are laquinimod, an orally administered small molecule with unique
immunomodulatory properties for the treatment of multiple sclerosis, as well as
ANYARA for use in cancer targeted therapy, primarily of renal cancer. Further
key projects in clinical development comprise the three orally administered
compounds TASQ for prostate cancer, 57-57 for SLE and RhuDex(TM) for RA. Please

visitwww.activebiotech.com for more information.

Active Biotech AB
PO Box 724, SE-220 07 Lund
Sweden
Tel: +46 (0)46-19 20 00
Fax: +46 (0)46-19 11 00

 Active Biotech is required under the Securities Markets Act to make the
information in this press release public. The information was submitted for
publication at 08:30 am CET on June 10, 2010.





[HUG#1422765]





Active Biotech Capital Markets Day: http://hugin.info/1002/R/1422765/371786.pdf

Weitere Infos zu dieser Pressemeldung:
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
Datum: 10.06.2010 - 08:30 Uhr
Sprache: Deutsch
News-ID 22204
Anzahl Zeichen: 0

contact information:
Town:

LUND

Kategorie:

Business News

Diese Pressemitteilung wurde bisher 250 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Active Biotech Capital Markets Day"
steht unter der journalistisch-redaktionellen Verantwortung von

Active Biotech (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Primary endpoint reached in Active Biotech's TASQ Phase II clinical trial i ...

Lund, Sweden, December 14, 2009 - A first analysis of the primary endpoint based on data from at least six months' treatment of more than 200 patients, has been performed in Active Biotech AB's (NASDAQ OMX Nordic: ACTI) ongoing Phase II cli ...

Active Biotech's election committee appointed ...

In accordance with a decision made by the Annual General Meeting held on May 7, 2009, the Election Committee shall comprise the representatives for the three largest shareholders on September 30 and the Board Chairman. For the 2010 Annual General ...

Active Biotech AB Interim Report, January - September 2009 ...

* Laquinimod -- new data presented at ECTRIMS * 57-57 -- exploratory clinical trial in progress * RhuDex(TM) -- clinical development to continue following feedback from UK MHRA * ANYARA -- complete Phase I data published * TASQ -- complete Phase I ...

Alle Meldungen von Active Biotech